Synapse - Shanu Modi

Results (269)

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
Cancer Research (2017)

Fulltext@MSK | Save

Phase 1 study of the antibody-drug conjugate (ADC) SGN-LIV1A in patients with heavily pretreated metastatic breast cancer

Meeting Abstract

Forero-Torres, A.; Modi, S.; Specht, J.; Miller, K.; Weise, A.; Burris, H.; Liu, M.; Krop, I.; Pusztai, L.; Kostic, A.; more...
Cancer Research (2017)

Fulltext@MSK | Save

Pathologic complete response with neoadjuvant doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single center experience

Journal Article

Singh, J. C.; Mamtani, A.; Barrio, A.; Morrow, M.; Sugarman, S.; Jones, L. W.; Yu, A. F.; Argolo, D.; Smyth, L. M.; Modi, S.; more...
The Oncologist (2017)

Fulltext@MSK | Save

A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (pts) with solid tumors

Meeting Abstract

Modi, S.; Eder, J. P.; Lorusso, P.; Weekes, C.; Chandarlapaty, S.; Tolaney, S. M.; McLaughlin, J.; Camidge, D. R.; Chang, C. W.; Nazzal, D.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Meeting Abstract

Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

The epichaperome is an integrated chaperome network that facilitates tumour survival

Journal Article

Rodina, A.; Wang, T.; Yan, P.; Gomes, E. D.; Dunphy, M. P. S.; Pillarsetty, N.; Koren, J. 3rd; Gerecitano, J. F.; Taldone, T.; Zong, H.; more...
Nature (2016)

Fulltext@MSK | Save

Biomarkers that predict sensitivity to heat shock protein 90 inhibitors

Journal Article

Jhaveri, K.; Chandarlapaty, S.; Iyengar, N.; Morris, P. G.; Corben, A. D.; Patil, S.; Akram, M.; Towers, R.; Sakr, R. A.; King, T. A.; more...
Clinical Breast Cancer (2016)

Fulltext@MSK | Save

Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial

Meeting Abstract

Hyman, D. M.; Piha-Paul, S. A.; Rodón, J.; Saura, C.; Puzanov, I.; Shapiro, G. I.; Loi, S.; Joensuu, H.; Hanrahan, A. J.; Modi, S.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience

Meeting Abstract

Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
Cancer Research (2016)

Fulltext@MSK | Save

Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2- advanced breast cancer

Meeting Abstract

Bardia, A.; Modi, S.; Oliveira, M.; Campone, M.; Ma, B.; Dirix, L.; Weise, A.; Nardi, L.; Zhang, V.; Bhansali, S. G.; more...
Cancer Research (2016)

Fulltext@MSK | Save